Cingulate Inc.
CING$66M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaKANSAS CITY
Clinical-stage pharmaceutical company developing ADHD treatments
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 18, 2026
7wMarket Overview
Stock performance and key metrics
CING News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
CTx-1301 - Dexmethylphenidate 25mg
ADHD
CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
ADHD
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
ADHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTx-1301 - Dexmethylphenidate 25mg | Phase 3 | ADHD | - | - |
CTx-1301-Dexmethylphenidate 12.5 mg (titration only) | Phase 3 | ADHD | - | - |
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release | Phase 2 | ADHD | - | - |
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply